CUREVAC NV (CVAC) Stock Fundamental Analysis
NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
Taking everything into account, CVAC scores 6 out of 10 in our fundamental rating. CVAC was compared to 555 industry peers in the Biotechnology industry. While CVAC has a great health rating, its profitability is only average at the moment. CVAC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CVAC had positive earnings in the past year.
CVAC had a positive operating cash flow in the past year.
CVAC had negative earnings in 4 of the past 5 years.
In multiple years CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
CVAC's Return On Assets of 24.34% is amongst the best of the industry. CVAC outperforms 98.56% of its industry peers.
CVAC's Return On Equity of 27.94% is amongst the best of the industry. CVAC outperforms 97.48% of its industry peers.
The Return On Invested Capital of CVAC (24.75%) is better than 98.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROIC | 24.75% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 34.50%, CVAC belongs to the top of the industry, outperforming 97.48% of the companies in the same industry.
With an excellent Operating Margin value of 37.87%, CVAC belongs to the best of the industry, outperforming 98.74% of the companies in the same industry.
Looking at the Gross Margin, with a value of 87.59%, CVAC belongs to the top of the industry, outperforming 90.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CVAC is creating value.
The number of shares outstanding for CVAC remains at a similar level compared to 1 year ago.
The number of shares outstanding for CVAC has been increased compared to 5 years ago.
The debt/assets ratio for CVAC has been reduced compared to a year ago.
2.2 Solvency
CVAC has an Altman-Z score of 9.91. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
CVAC has a better Altman-Z score (9.91) than 86.85% of its industry peers.
The Debt to FCF ratio of CVAC is 0.26, which is an excellent value as it means it would take CVAC, only 0.26 years of fcf income to pay off all of its debts.
CVAC's Debt to FCF ratio of 0.26 is amongst the best of the industry. CVAC outperforms 96.04% of its industry peers.
CVAC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, CVAC is doing worse than 62.52% of the companies in the same industry.
Although CVAC does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Altman-Z | 9.91 |
ROIC/WACC3.47
WACC7.13%
2.3 Liquidity
CVAC has a Current Ratio of 7.65. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CVAC (7.65) is better than 69.01% of its industry peers.
A Quick Ratio of 7.64 indicates that CVAC has no problem at all paying its short term obligations.
The Quick ratio of CVAC (7.64) is better than 69.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 166.39%, which is quite impressive.
The Revenue has grown by 787.58% in the past year. This is a very strong growth!
Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
The Revenue is expected to decrease by -11.04% on average over the next years. This is quite bad
EPS Next Y-174.05%
EPS Next 2Y-64.42%
EPS Next 3Y-33.29%
EPS Next 5Y-22.5%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.12%
Revenue Next 5Y-11.04%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CVAC is valuated cheaply with a Price/Earnings ratio of 5.72.
98.56% of the companies in the same industry are more expensive than CVAC, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.15. CVAC is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.72 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.28% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CVAC indicates a rather cheap valuation: CVAC is cheaper than 98.20% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.3 | ||
| EV/EBITDA | 2.89 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
CVAC's earnings are expected to decrease with -33.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.42%
EPS Next 3Y-33.29%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.43
+0.05 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.7%
Inst Owner Change-0.53%
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap1.22B
Analysts78.46
Price Target5.26 (-3.13%)
Short Float %4.38%
Short Ratio3.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.37%
Min EPS beat(2)-18.68%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)39.95%
Min EPS beat(4)-18.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)0.33%
EPS beat(12)5
Avg EPS beat(12)-6.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.68%
Min Revenue beat(2)-86.88%
Max Revenue beat(2)118.24%
Revenue beat(4)3
Avg Revenue beat(4)139.54%
Min Revenue beat(4)-86.88%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)58.85%
Revenue beat(12)5
Avg Revenue beat(12)30.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.77%
PT rev (3m)-33.11%
EPS NQ rev (1m)-311.11%
EPS NQ rev (3m)20.83%
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-4.95%
Revenue NQ rev (1m)-33.33%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)7.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.72 | ||
| Fwd PE | N/A | ||
| P/S | 1.99 | ||
| P/FCF | 7.3 | ||
| P/OCF | 6.65 | ||
| P/B | 1.62 | ||
| P/tB | 1.68 | ||
| EV/EBITDA | 2.89 |
EPS(TTM)0.95
EY17.5%
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)0.74
FCFY13.7%
OCF(TTM)0.82
OCFY15.03%
SpS2.72
BVpS3.36
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROCE | 29.12% | ||
| ROIC | 24.75% | ||
| ROICexc | 70.54% | ||
| ROICexgc | 78.69% | ||
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% | ||
| FCFM | 27.34% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.88% | ||
| Cap/Sales | 2.65% | ||
| Interest Coverage | 85.86 | ||
| Cash Conversion | 72.42% | ||
| Profit Quality | 79.25% | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 | ||
| Altman-Z | 9.91 |
F-Score8
WACC7.13%
ROIC/WACC3.47
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-174.05%
EPS Next 2Y-64.42%
EPS Next 3Y-33.29%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.12%
Revenue Next 5Y-11.04%
EBIT growth 1Y168.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-145%
EBIT Next 3Y-28.88%
EBIT Next 5Y10.78%
FCF growth 1Y142.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y162.99%
OCF growth 3YN/A
OCF growth 5YN/A